Skip to main content
OpenTrials
Completed

NCT Number: NCT04064034

ALateral Flow Assay to Detect QSOX1 Peptide in Patients With or at Risk for Pancreatic Cancer

Researchers have developed a new test to measure a protein QSOX1 that is found to be elevated in subjects with pancreas cancer. Researchers are looking to use this test to compare subjects with pancreas cancer and subjects without pancreas cancer to see if this test could be used to diagnosis pancreas cancer.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pancreas Cancer Cysts Digestive System Diseases Digestive System Neoplasms Endocrine Gland Neoplasms Endocrine System Diseases Neoplasms Neoplasms by Site Pancreas Cyst Pancreatic Cyst Pancreatic Diseases Pancreatic Neoplasms

Age range

17 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Mayo Clinic in Arizona

Scottsdale, Arizona, 85259, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients with biopsy-proven adenocarcinoma prior to receiving any therapy such as surgery, radiation or chemotherapy.
  • Patients without pancreas cancer.
  • Adult patients with benign pancreas disorders such as pancreatitis with imaging within 12 months (CT, MRI, EUS) documenting no cancer.
  • Healthy adults with blood specimens in an existing biobank.
  • Patients with pancreatic cystic lesions.
  • Adult patients undergoing clinically indicated EUS-guided FNA biopsy of pancreatic cystic lesions.

Exclusion criteria

  • Prior treatment for pancreas cancer.
  • Unable or unwilling to give consent.

Treatment and study plan

Lateral Flow Assay (LFA)

Other

Test to detect the Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein

Primary outcomes

  1. Quiescin Sulfhydryl Oxidase 1 (QSOX1) in the blood

    Time frame: Baseline

    Number of subjects with the presence and concentration of QSOX1 peptide found in the blood samples by the lateral flow assay (LFA) test

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Registry information

Official study title

Evaluation of the Diagnostic Potential a Lateral Flow Assay to Detect QSOX1 Peptide in Patients With or at Risk for Pancreatic Cancer

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
Aug 21, 2019
Registry last updated
Dec 2, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.